Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)

被引：0

作者：

Nobuaki Suzuki

Shoichi Hazama

Takeshi Nagasaka

Hiroaki Tanioka

Yasuo Iwamoto

Yuji Negoro

Masami Yamauchi

Michiya Kobayashi

Hiroshi Okuda

Noriaki Fujishima

Taku Nishimura

Naoki Yamanaka

Kazuhiro Toyota

Yoshiko Mori

Yuki Nakagami

Mototsugu Shimokawa

Hiroaki Nagano

Masazumi Okajima

机构：

[1] Yamaguchi University Graduate School of Medicine,Department of Gastroenterological, Breast and Endocrine Surgery

[2] Yamaguchi University School of Medicine,Department of Translational Research and Developmental Therapeutics Against Cancer

[3] Kawasaki Medical School,Department of Clinical Oncology

[4] Hiroshima City Hiroshima Citizens Hospital,Department of Medical Oncology

[5] Kochi Health Sciences Center,Department of Medical Oncology

[6] Hiroshima Prefectural Hospital,Division of Clinical Oncology

[7] Kochi Medical School Hospital,Cancer Treatment Center

[8] Onomichi General Hospital,Surgery and Endoscopic Surgery

[9] Fukuda Clinic of Internal Medicine,Department of Surgery

[10] Heart and Digestive,Department of Surgery

[11] Kokura Memorial Hospital,Department of Surgery

[12] Japanese Red Cross Yamaguchi Hospital,Department of Surgery

[13] National Hospital Organization Higashihiroshima Medical Center,Department of Gastroenterological Surgery

[14] Okayama University Graduate School of Medicine,Cancer Biostatistics Laboratory, Clinical Research Institute

[15] Dentistry and Pharmaceutical Sciences,Department of Surgery

[16] National Kyushu Cancer Center,undefined

[17] Hiroshima City Hiroshima Citizens Hospital,undefined

来源：

International Journal of Clinical Oncology | 2019年 / 24卷

关键词：

Bevacizumab; CAPIRI; Biweekly; Second line; mCRC;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1223 / 1230

页数：7

共 50 条

[31] Efficacy and safety of CapeIRI plus bevacizumab therapy as a second-line treatment for patients with metastatic colorectal cancer
Sunagawa, Y.
Nakayama, G.
Hattori, N.
Ezaka, K.
Uda, H.
Umeda, S.
Sato, B.
Yamada, S.
Sugimito, H.
Koike, M.
Kodera, Y.
ANNALS OF ONCOLOGY, 2017, 28
[32] Comparative analysis of the effectiveness of second-line bevacizumab plus chemotherapy in second-line therapy in metastatic colorectal cancer.
Smagulova, Kaldigul
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
[33] Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study)
Nakayama, Goro
Mitsuma, Ayako
Sunagawa, Yuki
Ishigure, Kiyoshi
Yokoyama, Hiroyuki
Matsui, Takanori
Nakayama, Hiroshi
Nakata, Kazuhiko
Ishiyama, Akiharu
Asada, Takahiro
Umeda, Shinichi
Ezaka, Kazuhiro
Hattori, Norifumi
Takami, Hideki
Kobayashi, Daisuke
Tanaka, Chie
Kanda, Mitsuro
Yamada, Suguru
Koike, Masahiko
Fujiwara, Michitaka
Fujii, Tsutomu
Murotani, Kenta
Ando, Yuichi
Kodera, Yasuhiro
ONCOLOGIST, 2018, 23 (08): : 919 - 927
[34] Phase II study of irinotecan and bevacizumab plus alternate day S-1 as second-line treatment in patients with metastatic colorectal cancer.
Tanaka, Chihiro
Matsuda, Chu
Kondo, Ken
Tokunaga, Yukihiko
Takahashi, Takao
Kosugi, Chihiro
Takemoto, Hiroyoshi
Iwamoto, Shigeyoshi
Oba, Koji
Sakamoto, Junichi
Mishima, Hideyuki
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[35] The TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer.
Kuboki, Yasutoshi
Terazawa, Tetsuji
Masuishi, Toshiki
Nakamura, Masato
Watanabe, Jun
Ojima, Hitoshi
Shinohara, Yudai
Kotaka, Masahito
Hara, Hiroki
Ohta, Takashi
Oki, Eiji
Sunakawa, Yu
Ishihara, Soichiro
Taniguchi, Hiroya
Nakajima, Takako Eguchi
Morita, Satoshi
Shirao, Kuniaki
Yoshino, Takayuki
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[36] Capecotabome plus cetuximab as second-line chemotherapy in elderly patients with metastatic colorectal cancer: Results of a phase II study
Rozzi, A.
Corona, M.
Nardoni, C.
Petricola, F.
Restuccia, M.
Lanzetta, G.
ANNALS OF ONCOLOGY, 2008, 19 : 86 - 86
[37] Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer
Hejna, M
Köstler, WJ
Raderer, M
Tomek, S
Brodowicz, T
Scheithauer, W
Wiltschke, C
Zielinski, CC
ANTI-CANCER DRUGS, 2000, 11 (08) : 629 - 634
[38] Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer
Zhang, Jing
Yang, Wenwei
Liu, Junbao
Wang, Nan
Ren, Zhaoying
Yang, Tingting
Xie, Gongli
Wu, Guifu
Sun, Yongkun
INVESTIGATIONAL NEW DRUGS, 2024, 42 (04) : 454 - 461
[39] Capecitabine plus paclitaxel as first-or second-line therapy: a multicenter phase II study in metastatic breast cancer.
Meza, LA
Amin, B
Hill, T
Chen, YM
Petralia, SA
Gradishar, WJ
BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 271 - 271
[40] A Phase I/II Study of XELIRI Plus Bevacizumab as Second-Line Chemotherapy for Japanese PatientsWithMetastatic Colorectal Cancer (BIX Study)
Hamamoto, Yasuo
Yamaguchi, Tatsuro
Nishina, Tomohiro
Yamazaki, Kentaro
Ura, Takashi
Nakajima, Takako
Goto, Ayumu
Shimada, Ken
Nakayama, Norisuke
Sakamoto, Junichi
Yamada, Yasuhide
ONCOLOGIST, 2014, 19 (11): : 1131 - 1132

← 1 2 3 4 5 →